Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic transplant is curative for many patients with hematological
neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal
toxicity are still under way. Clofarabine is a newly licensed agent with dramatic
anti-leukemic activity. Its incorporation into a regimen for pre-transplant conditioning of
acute leukemia and lymphoma patients is logical, exploiting both the anti-tumor activities it
is recognized to have and the immunosuppressive activity seen with drugs in its class.